An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

  • Hayslip, John (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date7/13/1312/31/15